Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on July 22, 2019. The report addresses a material corporate governance event regarding the departure of a senior executive.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the resignation of Yossi Maimon from his positions as Vice President and Chief Financial Officer, effective July 22, 2019. Mr. Maimon is departing to pursue other opportunities.
Outlook, Management Commentary, and Risks
- Succession Plan: The Company intends to appoint a new Chief Financial Officer soon.
- Transition: Mr. Maimon will continue to work with the finance and accounting teams to ensure a smooth transition of financial and accounting functions pending the appointment of his successor.
- Risks: The filing does not explicitly detail new risks, though the departure of a CFO inherently introduces operational transition risks until a replacement is secured.
Key Facts for Investor Verification
- Confirmation of the exact effective date of the CFO resignation (July 22, 2019).
- Timeline for the appointment of the new Chief Financial Officer.
- Any potential impact on the Company's ongoing financial reporting or audit processes during the transition period.